Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Rating of “Buy” from Brokerages
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has been assigned a consensus rating of “Buy” from the sixteen research firms that are covering the stock, MarketBeat.com reports. Sixteen equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have updated their coverage on the […]
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has been assigned a consensus rating of “Buy” from the sixteen research firms that are covering the stock, MarketBeat.com reports. Sixteen equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have updated their coverage on the […]
